164 related articles for article (PubMed ID: 25179409)
1. Preappointment testing for BRAF/KIT mutation in advanced melanoma: a model in molecular data delivery for individualized medicine.
Mounajjed T; Brown CL; Stern TK; Bjorheim AM; Bridgeman AJ; Rumilla KM; McWilliams RR; Flotte TJ
Hum Pathol; 2014 Nov; 45(11):2240-6. PubMed ID: 25179409
[TBL] [Abstract][Full Text] [Related]
2.
Ponti G; Manfredini M; Greco S; Pellacani G; Depenni R; Tomasi A; Maccaferri M; Cascinu S
Anticancer Res; 2017 Dec; 37(12):7043-7048. PubMed ID: 29187493
[TBL] [Abstract][Full Text] [Related]
3. Prevalence of BRAF, NRAS and c-KIT mutations in Slovenian patients with advanced melanoma.
Moltara ME; Novakovic S; Boc M; Bucic M; Rebersek M; Zadnik V; Ocvirk J
Radiol Oncol; 2018 Apr; 52(3):289-295. PubMed ID: 30210039
[TBL] [Abstract][Full Text] [Related]
4. Mutation analysis of BRAF and KIT in circulating melanoma cells at the single cell level.
Sakaizawa K; Goto Y; Kiniwa Y; Uchiyama A; Harada K; Shimada S; Saida T; Ferrone S; Takata M; Uhara H; Okuyama R
Br J Cancer; 2012 Feb; 106(5):939-46. PubMed ID: 22281663
[TBL] [Abstract][Full Text] [Related]
5. Mutation scanning of BRAF, NRAS, KIT, and GNAQ/GNA11 in oral mucosal melanoma: a study of 57 cases.
Lyu J; Wu Y; Li C; Wang R; Song H; Ren G; Guo W
J Oral Pathol Med; 2016 Apr; 45(4):295-301. PubMed ID: 26399561
[TBL] [Abstract][Full Text] [Related]
6. BRAF, KIT and NRAS mutations and expression of c-KIT, phosphorylated extracellular signal-regulated kinase and phosphorylated AKT in Japanese melanoma patients.
Oyama S; Funasaka Y; Watanabe A; Takizawa T; Kawana S; Saeki H
J Dermatol; 2015 May; 42(5):477-84. PubMed ID: 25766129
[TBL] [Abstract][Full Text] [Related]
7. BRAF, NRAS and KIT sequencing analysis of spindle cell melanoma.
Kim J; Lazar AJ; Davies MA; Homsi J; Papadopoulos NE; Hwu WJ; Bedikian AY; Woodman SE; Patel SP; Hwu P; Kim KB
J Cutan Pathol; 2012 Sep; 39(9):821-5. PubMed ID: 22809251
[TBL] [Abstract][Full Text] [Related]
8. The molecular profile of metastatic melanoma in Australia.
Lyle M; Haydu LE; Menzies AM; Thompson JF; Saw RP; Spillane AJ; Kefford RF; Mann GJ; Cooper WA; Yu B; Scolyer RA; O'Toole SA; Long GV
Pathology; 2016 Feb; 48(2):188-93. PubMed ID: 27020391
[TBL] [Abstract][Full Text] [Related]
9. Assessment of clinical parameters associated with mutational status in metastatic malignant melanoma: a single-centre investigation of 141 patients.
Schlaak M; Bajah A; Podewski T; Kreuzberg N; von Bartenwerffer W; Wardelmann E; Merkelbach-Bruse S; Büttner R; Mauch C; Kurschat P
Br J Dermatol; 2013 Apr; 168(4):708-16. PubMed ID: 23528057
[TBL] [Abstract][Full Text] [Related]
10. Relevance of BRAF Subcellular Localization and Its Interaction with
Beleaua MA; Jung I; Braicu C; Milutin D; Gurzu S
Int J Mol Sci; 2021 Nov; 22(21):. PubMed ID: 34769348
[TBL] [Abstract][Full Text] [Related]
11. Human malignant melanoma: detection of BRAF- and c-kit-activating mutations by high-resolution amplicon melting analysis.
Willmore-Payne C; Holden JA; Tripp S; Layfield LJ
Hum Pathol; 2005 May; 36(5):486-93. PubMed ID: 15948115
[TBL] [Abstract][Full Text] [Related]
12. Testing for
Le Flahec G; Briolais M; Guibourg B; Lemasson G; Grippari JL; Ledé F; Marcorelles P; Uguen A
J Clin Pathol; 2020 Feb; 73(2):116-119. PubMed ID: 31506288
[TBL] [Abstract][Full Text] [Related]
13. Pathologist initiated reflex BRAF mutation testing in metastatic melanoma: experience at a specialist melanoma treatment centre.
Potter AJ; Colebatch AJ; Rawson RV; Ferguson PM; Cooper WA; Gupta R; O'Toole S; Saw RPM; Ch'ng S; Menzies AM; Long GV; Scolyer RA
Pathology; 2022 Aug; 54(5):526-532. PubMed ID: 35249747
[TBL] [Abstract][Full Text] [Related]
14. Molecular testing in malignant melanoma.
Grossmann AH; Grossmann KF; Wallander ML
Diagn Cytopathol; 2012 Jun; 40(6):503-10. PubMed ID: 22619125
[TBL] [Abstract][Full Text] [Related]
15. Oncogene abnormalities in a series of primary melanomas of the sinonasal tract: NRAS mutations and cyclin D1 amplification are more frequent than KIT or BRAF mutations.
Chraybi M; Abd Alsamad I; Copie-Bergman C; Baia M; André J; Dumaz N; Ortonne N
Hum Pathol; 2013 Sep; 44(9):1902-11. PubMed ID: 23664541
[TBL] [Abstract][Full Text] [Related]
16. BRAF and c-kit gene copy number in mutation-positive malignant melanoma.
Willmore-Payne C; Holden JA; Hirschowitz S; Layfield LJ
Hum Pathol; 2006 May; 37(5):520-7. PubMed ID: 16647948
[TBL] [Abstract][Full Text] [Related]
17. Prognostic and predictive values of oncogenic BRAF, NRAS, c-KIT and MITF in cutaneous and mucous melanoma.
Pracht M; Mogha A; Lespagnol A; Fautrel A; Mouchet N; Le Gall F; Paumier V; Lefeuvre-Plesse C; Rioux-Leclerc N; Mosser J; Oger E; Adamski H; Galibert MD; Lesimple T
J Eur Acad Dermatol Venereol; 2015 Aug; 29(8):1530-8. PubMed ID: 25623140
[TBL] [Abstract][Full Text] [Related]
18. Comparative analysis of BRAF, NRAS and c-KIT mutation status between tumor tissues and autologous tumor cell-lines of stage III/IV melanoma.
Knol AC; Pandolfino MC; Vallée A; Nguyen F; Lella V; Khammari A; Denis M; Puaux AL; Dréno B
Exp Dermatol; 2015 Jan; 24(1):70-3. PubMed ID: 25363723
[TBL] [Abstract][Full Text] [Related]
19. KIT, NRAS, BRAF and PTEN mutations in a sample of Swedish patients with acral lentiginous melanoma.
Zebary A; Omholt K; Vassilaki I; Höiom V; Lindén D; Viberg L; Kanter-Lewensohn L; Johansson CH; Hansson J
J Dermatol Sci; 2013 Dec; 72(3):284-9. PubMed ID: 23993026
[TBL] [Abstract][Full Text] [Related]
20. Assessment of BRAF and KIT mutations in Japanese melanoma patients.
Ashida A; Uhara H; Kiniwa Y; Oguchi M; Murata H; Goto Y; Uchiyama A; Ogawa E; Hayashi K; Koga H; Okuyama R
J Dermatol Sci; 2012 Jun; 66(3):240-2. PubMed ID: 22534474
[No Abstract] [Full Text] [Related]
[Next] [New Search]
